Celladon Corp.
This article was originally published in Start Up
Executive Summary
Celladon aims to reverse the downhill spiral of cardiomyocyte damage in heart failure. Its first product is a form of gene therapy, delivered by a recombinant adeno-associated viral vector, designed to augment SERCA2a-mediated calcium transport in HF patients. The SERCA2a pathway is pivotal in controlling the heart's pumping ability, and numerous studies have correlated heart failure progression with declines in SERCA2a levels.
You may also be interested in...
Where Are They Now? Checking In On Four Cardiovascular Start-Ups
It's no secret increasing generic competition and regulatory oversight, combined with the financial challenges of developing a primary care drug, make cardiovascular a tough place for venture-backed biotechs. START-UP takes the pulse of four previously profiled cardiovascular companies -- arca Biopharma, Celladon, NovaCardia and Portola Pharmaceuticals, -- to see what lessons they've learned.
Where Are They Now? Checking In On Four Cardiovascular Start-Ups
It's no secret increasing generic competition and regulatory oversight, combined with the financial challenges of developing a primary care drug, make cardiovascular a tough place for venture-backed biotechs. START-UP takes the pulse of four previously profiled cardiovascular companies -- arca Biopharma, Celladon, NovaCardia and Portola Pharmaceuticals, -- to see what lessons they've learned.
Celladon Hopes To Bring Gene-Therapy Solution To Heart Failure Patients
Improving heart contractility by increasing levels of the SERCA2a gene is a new approach to a familiar problem in treating heart failure.